Voyager Therapeutics, Inc. (VYGR) Stock
Key stats
- Market cap
- $109.52M
- Price / Earnings ratio
- -1.1x
- EPS (TTM)
- -$1.74
- Volume
- Loading
- 52-week high
- $5.48
- 52-week low
- $1.68
Source: third-party data provider, as of November 13, 2026
Compare with VYGR
Recent news

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
VYGR

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
VYGR

UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches
UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches
VYGR

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
VYGR
Technical indicators
- RSI 14
- 39.05
- MACD 12/26/9
- -0.17
- EMA 9 of MACD
- -0.21
- MACD histogram
- 0.04
- SMA 50
- $2.45
- Price below SMA 50
- EMA 50
- $2.32
- Price below EMA 50
- SMA 200
- $3.38
- Price below SMA 200
- EMA 200
- $3.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
VYGR

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
VYGR

UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches
UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches
VYGR

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
VYGR

Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
VYGR

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
VYGR

7 Biotech Stocks to Buy for Their Game-Changing Potential
7 Biotech Stocks to Buy for Their Game-Changing Potential
VYGR

New Strong Buy Stocks for May 1st
New Strong Buy Stocks for May 1st
VYGR

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
VYGR

Cheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20
Cheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20
VYGR
About Voyager Therapeutics, Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the CEO | 1977 |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder | — |
| Dr. Mark A. Kay M.D., Ph.D. | Founder | 1958 |
| Ms. Amy Quinlan | Principal Accounting Officer | 1975 |
| Mr. Todd Carter Ph.D. | Chief Scientific Officer | 1970 |
| Dr. Mathieu Nonnenmacher Ph.D. | Vice President of Gene Therapy | — |
| Mihalis Kariolis | Vice President of Non-Viral Therapeutics | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 39.05
- MACD 12/26/9
- -0.17
- EMA 9 of MACD
- -0.21
- MACD histogram
- 0.04
- SMA 50
- $2.45
- Price below SMA 50
- EMA 50
- $2.32
- Price below EMA 50
- SMA 200
- $3.38
- Price below SMA 200
- EMA 200
- $3.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.1 | -6.6 | ||||||||||
| 2022 | -4.3 | +29.7 | +94.9 | -12.0 | -22.9 | -3.6 | +10.2 | -7.2 | -7.9 | -8.0 | +12.7 | +1.0 |
| 2023 | +56.8 | -23.3 | +7.2 | -10.7 | +57.3 | -2.6 | -17.2 | +8.9 | -23.3 | -9.3 | +10.8 | +10.9 |
| 2024 | -19.2 | +10.1 | -1.4 | -25.8 | +0.5 | -8.6 | +11.6 | |||||
| 2026 | -2.0 | +2.5 | -7.0 | -6.5 | +2.9 | -7.7 | -15.8 | +15.0 | -21.9 | -35.8 | -1.1 |



